Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis
E Balsells, L Guillot, H Nair, MH Kyaw - PloS one, 2017 - journals.plos.org
Background Routine immunisation with pneumococcal conjugate vaccines (PCV7/10/13)
has reduced invasive pneumococcal disease (IPD) due to vaccine serotypes significantly …
has reduced invasive pneumococcal disease (IPD) due to vaccine serotypes significantly …
Community-acquired bacterial meningitis
D van de Beek, M Brouwer, R Hasbun… - Nature reviews Disease …, 2016 - nature.com
Meningitis is an inflammation of the meninges and subarachnoid space that can also involve
the brain cortex and parenchyma. It can be acquired spontaneously in the community …
the brain cortex and parenchyma. It can be acquired spontaneously in the community …
Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national …
B Wahl, KL O'Brien, A Greenbaum… - The Lancet Global …, 2018 - thelancet.com
Background Pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b
(Hib) vaccine are now used in most countries. To monitor global and regional progress …
(Hib) vaccine are now used in most countries. To monitor global and regional progress …
Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite …
MR Moore, R Link-Gelles, W Schaffner… - The Lancet Infectious …, 2015 - thelancet.com
Background In 2000, seven-valent pneumococcal conjugate vaccine (PCV7) was introduced
in the USA and resulted in dramatic reductions in invasive pneumococcal disease (IPD) and …
in the USA and resulted in dramatic reductions in invasive pneumococcal disease (IPD) and …
[HTML][HTML] Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an …
Background The 13-valent pneumococcal conjugate vaccine (PCV13) protects against key
serotypes that increased after routine immunisation with the seven-valent vaccine (PCV7) …
serotypes that increased after routine immunisation with the seven-valent vaccine (PCV7) …
[HTML][HTML] Serotype replacement after introduction of 10-valent and 13-valent pneumococcal conjugate vaccines in 10 countries, Europe
G Hanquet, P Krizova, T Dalby… - Emerging infectious …, 2022 - ncbi.nlm.nih.gov
We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal
conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) …
conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) …
Effects of vaccination on invasive pneumococcal disease in South Africa
A Von Gottberg, L De Gouveia, S Tempia… - … England Journal of …, 2014 - Mass Medical Soc
Background In South Africa, a 7-valent pneumococcal conjugate vaccine (PCV7) was
introduced in 2009 with a three-dose schedule for infants at 6, 14, and 36 weeks of age; a 13 …
introduced in 2009 with a three-dose schedule for infants at 6, 14, and 36 weeks of age; a 13 …
Acute bacterial meningitis in adults
Over the past several decades, the incidence of bacterial meningitis in children has
decreased but there remains a significant burden of disease in adults, with a mortality of up …
decreased but there remains a significant burden of disease in adults, with a mortality of up …
The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology
Background: The test-negative design is an increasingly popular approach for estimating
vaccine effectiveness (VE) due to its efficiency. This review aims to examine published test …
vaccine effectiveness (VE) due to its efficiency. This review aims to examine published test …
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active …
H Platt, T Omole, J Cardona, NJ Fraser… - The Lancet Infectious …, 2023 - thelancet.com
Background A pneumococcal conjugate vaccine (PCV) specifically focused on serotypes
associated with adult residual disease burden is urgently needed. We aimed to assess …
associated with adult residual disease burden is urgently needed. We aimed to assess …